THYROCARE2026-09-21THYROCARE2026-09-212026-09-21iso4217:INRxbrli:pure539871Thyrocare Technologies LimitedTHYROCARENOTLISTEDINE594H01019NewAcquisition (including agreement to acquire)true2026-09-2114:50:002026-09-21Sale and transfer of the entire equity shareholding held by the Company in Nueclear Healthcare Limited (“NHL”), a material wholly owned subsidiary of the Company , comprising 1,11,11,000 (One Crore Eleven Lakh Eleven Thousand) equity shares, representing 100% of the issued, subscribed and paid-up equity share capital of NHL, to Trovera Healthcare Private Limited (“Trovera” or “Purchaser”), pursuant to a Share Purchase Agreement (“SPA”). <BR> <BR> The acquisition of the CCPS is being undertaken as part of the consideration for the proposed sale of the Company's entire shareholding in NHL to Trovera. The Company will acquire 42,500 CCPS of Trovera, having a face value of Rs. 10/- each and issued at a premium of Rs. 13,990/- per CCPS, as part consideration for the proposed sale. The balance consideration will be payable in cash. <BR> <BR> The acquisition of the CCPS is directly linked to and forms part of the consideration for the sale of the Company's entire shareholding in NHL. Accordingly, for share swap ratio, we have mentioned 1:1 only for validation purposeThyrocare Technologies LimitedListed Entity (self)Trovera Healthcare Private Limited000Trovera Healthcare Private Limited was incorporated on June 16, 2026 and does not have latest audited financial parameter.falsefalsetrueHealthcare ServicesThe acquisition of the CCPS of Trovera forms part of the consideration for the proposed sale of the Company's entire shareholding in NHL. Trovera's business is within the broad healthcare and diagnostics sector, which is aligned with the Company's business. The acquisition of the CCPS is directly linked to and incidental to the proposed divestment of NHLNofalseThe acquisition is expected to be completed by November, 30, 2026, subject to satisfaction of the applicable conditions precedent and receipt of requisite approvals.Cash and Shares1:1819000000The acquisition of the CCPS is being undertaken as part of the consideration for the proposed sale of the Company's entire shareholding in NHL to Trovera. The Company will acquire 42,500 CCPS of Trovera, having a face value of Rs. 10/- each and issued at a premium of Rs. 13,990/- per CCPS, as part consideration for the proposed sale. The balance consideration will be payable in cash.595000000000Trovera Healthcare Private Limited was incorporated on June 16, 2026 and is engaged in the business of healthcare and diagnostic services. As the company was incorporated during FY 2026-27, audited turnover for the preceding three financial years is not applicable. Trovera has presence in India.2026-06-16IndiaThe sale and transfer of the entire equity shareholding held by the Company in Nueclear Healthcare Limited (“NHL”), a material wholly owned subsidiary of the Company , comprising 1,11,11,000 (One Crore Eleven Lakh Eleven Thousand) equity shares, representing 100% of the issued, subscribed and paid-up equity share capital of NHL, to Trovera Healthcare Private Limited (“Trovera” or “Purchaser”), pursuant to a Share Purchase Agreement (“SPA”). As part of the consideration for the proposed sale of the Company's entire shareholding in Nueclear Healthcare Limited, Material Wholly Owned Subsidiary Company of the Company to Trovera, the Company will acquire 42,500 (Forty-Two Thousand Five Hundred) CCPS of Trovera. The CCPS will have a face value of Rs. 10/- (Rupees Ten only) each and will be issued at a premium of Rs. 13,990/- (Rupees Thirteen Thousand Nine Hundred Ninety only) per CCPS, in accordance with the agreed share swap terms and subject to the terms and conditions set out in the proposed SPA. The acquisition of the CCPS is directly linked to and forms part of the consideration for the sale of the Company's entire shareholding in NHL.